What Is Apigenin

Apigenin is a naturally occurring flavonoid, a subclass of plant polyphenols, found in high concentrations in chamomile, parsley, celery, and several other herbs and vegetables. It acts on multiple molecular targets in the body, including GABA receptors in the brain, the NAD+-consuming enzyme CD38, and inflammatory transcription factors. These properties have positioned it as a compound of interest in both sleep support and aging research.

Aging is accompanied by a steady decline in NAD+ levels, rising chronic inflammation, and deteriorating sleep quality. These three processes are interconnected: poor sleep accelerates inflammatory signaling, inflammation drives NAD+ consumption through increased CD38 expression, and falling NAD+ impairs the mitochondrial and DNA repair functions that keep cells resilient. A single compound that touches all three pathways simultaneously draws attention for its potential to address upstream drivers of biological aging rather than isolated symptoms.

Apigenin sits at this intersection. Its ability to inhibit CD38 provides a mechanistic route to preserving NAD+ that is distinct from precursor supplementation strategies like NMN or NR. Its action on GABA receptors offers a non-pharmacological means of supporting sleep architecture. And its modulation of NF-kB and COX-2 addresses the inflammatory side of the equation. Whether these in vitro and animal findings translate into clinically meaningful longevity benefits in humans remains an open question, but the biological logic behind the interest is coherent.

Apigenin's most widely discussed mechanism in the longevity space involves CD38 inhibition. CD38 is an ectoenzyme expressed on immune cells and many other tissues. Its primary substrate is NAD+, which it cleaves to produce cyclic ADP-ribose and other signaling molecules. As organisms age, CD38 expression increases, partly driven by chronic low-grade inflammation, and this is considered a major reason NAD+ levels decline with age. Apigenin binds to CD38 and reduces its enzymatic activity, which in animal models has been shown to preserve tissue NAD+ concentrations and support mitochondrial function.

At the neurological level, apigenin acts as a positive allosteric modulator of GABA-A receptors. Unlike benzodiazepines, which bind at the primary active site with high affinity, apigenin interacts at a different binding pocket and produces a subtler anxiolytic and sedative effect. This modulation reduces neuronal excitability, facilitating relaxation and sleep onset without the dependency risks or cognitive impairment associated with stronger GABAergic drugs.

Apigenin also suppresses the NF-kB pathway, a central regulator of inflammatory gene expression. By reducing NF-kB activation, it lowers the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. It additionally inhibits COX-2, the enzyme responsible for producing inflammatory prostaglandins. In certain cell models, apigenin has demonstrated pro-apoptotic effects in cancerous cells while sparing healthy tissue, though this area of research is preliminary and primarily confined to in vitro work. The compound also shows weak estrogenic activity through estrogen receptor beta, which may contribute to some of its anti-inflammatory and neuroprotective properties.

Apigenin supplements are available as isolated flavonoid capsules, chamomile extract standardized for apigenin content, and less commonly as sublingual tablets or liquid extracts. Isolated apigenin in capsule form offers the most precise dosing and is the format most commonly used in longevity-oriented protocols. Chamomile extract provides apigenin alongside other bioactive compounds like bisabolol and luteolin, which may have synergistic effects but make it harder to control exact apigenin intake.

Bioavailability is a notable consideration. Apigenin is poorly water-soluble and has limited absorption in its free form. Some manufacturers address this by using micronized particles or pairing the compound with lipid-based carriers. Taking apigenin alongside dietary fat may improve absorption. Glycosylated forms of apigenin, found naturally in plant foods, are converted to free apigenin by gut bacteria, which introduces variability based on individual microbiome composition.

Dosing strategies for apigenin vary considerably depending on the intended target. For sleep support, doses of 50 to 100 mg taken before bed are commonly used, reflecting the GABAergic mechanism that operates at relatively low concentrations. For CD38 inhibition and NAD+ preservation, some practitioners suggest doses in the 250 to 500 mg range, extrapolating from in vitro effective concentrations and animal pharmacokinetic data. It is worth noting that the translation from in vitro inhibitory concentrations to effective oral doses in humans is imprecise, and the higher end of this range lacks direct clinical validation.

Apigenin accumulates in tissues over time, particularly in fat-soluble compartments, so its effects may build with consistent use rather than appearing after a single dose. Cycling (periods of use followed by breaks) is sometimes recommended in longevity communities, though there is no published evidence establishing optimal cycling protocols.

When selecting an apigenin supplement, third-party testing for identity and purity is a baseline requirement. The compound should be verified as apigenin (4',5,7-trihydroxyflavone) rather than a loosely standardized herbal extract with unspecified flavonoid content. Certificates of analysis (COAs) should confirm the absence of heavy metals, pesticide residues, and microbial contamination. Products sourced from chamomile extraction should specify the apigenin percentage of the standardized extract.

Transparency about the source material matters. Apigenin can be synthesized or extracted from plant sources, and neither route is inherently superior, but the manufacturer should disclose which method is used. Products that list only "chamomile extract" without specifying apigenin content make it impossible to determine the actual dose per serving. Look for brands that provide batch-specific COAs and use recognized third-party testing laboratories.

The evidence base for apigenin spans cell studies, animal experiments, and a smaller body of human research. Its CD38 inhibition has been well characterized in vitro and confirmed in mouse models, where it preserved NAD+ levels and improved metabolic parameters in aged or obese animals. The anti-inflammatory properties have been demonstrated across numerous cell lines and animal models of inflammatory disease, showing consistent suppression of NF-kB and downstream cytokines. Apigenin's pro-apoptotic effects in cancer cell lines are among the more explored areas, though these findings have not translated into human clinical oncology applications.

Human data is more limited. Chamomile extract, standardized to apigenin content, has been studied in small randomized trials for generalized anxiety and sleep quality, with modest positive results. However, isolating apigenin's contribution from the other bioactive compounds in chamomile is methodologically difficult. Direct human trials using pure apigenin at doses commonly recommended in longevity protocols are essentially absent from the published literature. The NAD+ preservation hypothesis, while mechanistically sound and supported by animal data, has not been validated in controlled human studies measuring tissue NAD+ levels following apigenin supplementation. This gap between molecular plausibility and clinical proof is the most significant limitation of the current evidence.

Apigenin is generally well tolerated at dietary and moderate supplemental doses. It inhibits certain cytochrome P450 enzymes, particularly CYP2C9 and CYP1A2, which can alter the metabolism of drugs processed through these pathways, including warfarin, some statins, and caffeine. Its mild estrogenic activity through estrogen receptor beta is unlikely to cause clinically significant hormonal effects at typical doses, but individuals with hormone-sensitive conditions should be aware of this property. Sedative effects can compound with alcohol, benzodiazepines, or other CNS depressants. Pregnant or nursing individuals lack sufficient safety data for supplemental doses above those found in normal food consumption.